|
Market Research Report
U.S. Multiple Sclerosis Markets
| Published by |
Frost & Sullivan |
| Published |
September, 2007 |
Product code |
56326 |
| Content info |
77 Pages |
| Price |
|
|
U.S. Multiple Sclerosis Markets published by Frost & Sullivan in September, 2007. This report consists of 77 Pages and the price starts from US $ 6000.
Abstract
This research service provides revenue forecasts, market shares, projected
prevalence and treated populations, market trends, and existing and emerging
therapeutics. There is a competitive and product analysis of the major market
participants and products with competitive metrics for major and emerging
companies.
Table of Contents
1. EXECUTIVE SUMMARY
Executive Summary
2. MARKET INTRODUCTION
Introduction
- Multiple Sclerosis
- Scope and Segmentation
- Research Methodology
Disease Overview
- Causes of Multiple Sclerosis
- Classification of Multiple Sclerosis
- Treatment Options
Market Overview
- Market Engineering Measurements
- Market Trends
3. MARKET ANALYSIS
Product Analysis
- Interferons
- Copaxone
- Tysabri
- Novantrone
- Pipeline Drugs
Patient Forecasts
- Total Patient Forecasts
- Patient Forecast by Product
Revenue Forecasts
- Total Market Revenue Forecasts
- Revenue Forecasts by Product
Competitive Analysis
- Competitive Structure
- Company Market Share
Competitve Metrics
- Methodology and Metrics
- Biogen Idec
- Teva Pharmaceuticals
- EMD Serono
- Bayer Schering Pharma
- Emerging Companies
4. DECISION SUPPORT DATABASES
Demographic Indicators
Market Indicators
- World Multiple Sclerosis Prevalence
- U.S. Multiple Sclerosis Prevalence
- U.S. Multiple Sclerosis Incidence
- Pharmaceutical R&D Expenditure
|
